Literature DB >> 7194429

Lisuride in parkinsonism.

G Gopinathan, H Teräväinen, J M Dambrosia, C D Ward, J N Sanes, W K Stuart, E V Evarts, D B Calne.   

Abstract

We studied the actions of lisuride, a dopaminergic ergot derivative, in 20 parkinsonian patients. When the dose was increased gradually, most patients tolerated up to 5 mg daily. Clinical assessment and objective, computer-assisted evaluation revealed improvement in akinesia, rigidity and tremor. Adverse reactions were similar to those seen with levodopa and bromocriptine, but somnolence tended to occur more often with lisuride.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7194429     DOI: 10.1212/wnl.31.4.371

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  The behavioral pharmacology of hallucinogens.

Authors:  William E Fantegrossi; Kevin S Murnane; Chad J Reissig
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

Review 2.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

3.  Objective outcome criteria in trials of anti-parkinsonian therapy in the elderly: sensitivity, specificity and reliability of measures of brady- and hypo-kinesia.

Authors:  S G Bowes; P K Clark; A Charlett; C J O'Neill; A L Leeman; C Weller; P W Nicholson; A A Deshmukh; S M Dobbs; R J Dobbs
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 4.  Diagnosis and treatment of Parkinson disease: molecules to medicine.

Authors:  Joseph M Savitt; Valina L Dawson; Ted M Dawson
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

Review 5.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

6.  The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy.

Authors:  A Neophytides; A N Lieberman; M Goldstein; G Gopinathan; M Leibowitz; J Bock; R Walker
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-03       Impact factor: 10.154

7.  Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.

Authors:  K Jellinger
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

8.  Selective D-1 dopamine receptor agonist treatment of Parkinson's disease.

Authors:  A Braun; G Fabbrini; M M Mouradian; C Serrati; P Barone; T N Chase
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

9.  LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2009-11-25       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.